ERK upregulation caused by increasing FGFR3 level in HNSCC (head and neck squamous cell carcinoma) cells led to an increase in FGF2 expression, which correlated with reduced sensitivity to bevacizumab (Figure 2) [53]. The gene discussed is FGF2; the disease is head and neck squamous cell carcinoma.